Zealand Pharma Feed

2025-11-06 17:30:00 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

2025-10-17 17:05:17 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

2025-09-30 17:05:38 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 495,00 DKK | +7,35% | 256 MDKK

2025-09-24 17:00:59 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations 449,90 DKK | -4,32% | 148 MDKK

2025-09-11 22:00:00 Zealand Pharma increases its share capital as a result of the exercise of employee warrants 412,40 DKK | -4,14% | 133 MDKK

2025-09-11 17:00:00 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 412,40 DKK | -4,14% | 133 MDKK

2025-08-28 17:00:00 Zealand Pharma to participate in upcoming investor conferences in September 2025 437,40 DKK | -0,91% | 130 MDKK

2025-08-20 22:00:00 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. 411,60 DKK | +0,76% | 97,8 MDKK

2025-08-14 07:00:00 Zealand Pharma Announces Financial Results for the First Half of 2025 350,40 DKK | +2,73% | 190 MDKK

2025-08-07 17:30:00 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results 329,00 DKK | +1,08% | 97,1 MDKK

2025-07-18 18:30:00 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

2025-06-30 17:05:00 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 364,80 DKK | +2,85% | 273 MDKK

2025-06-18 17:29:59 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide 387,00 DKK | +1,71% | 287 MDKK

2025-06-06 22:00:00 Zealand Pharma increases its share capital as a result of the exercise of employee warrants

2025-06-02 07:00:00 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome 454,20 DKK | +0,15% | 311 MDKK

2025-05-27 22:00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 453,50 DKK | -0,83% | 1 920 MDKK

2025-05-19 15:00:00 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer 416,00 DKK | -0,26% | 136 MDKK

2025-05-12 07:00:00 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 425,90 DKK | -0,68% | 145 MDKK

2025-05-09 06:25:12 Zealand Pharma announces closing of collaboration and license agreement with Roche 428,80 DKK | +4,15% | 148 MDKK

2025-05-08 07:00:00 Zealand Pharma Announces Financial Results for the First Three Months of 2025 411,70 DKK | -8,37% | 250 MDKK

2025-05-01 17:05:00 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results 485,70 DKK | +4,12% | 142 MDKK

2025-04-24 07:00:00 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes 425,00 DKK | +4,68% | 127 MDKK

2025-04-23 15:00:00 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery 406,00 DKK | +2,40% | 150 MDKK

2025-04-19 22:05:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

2025-04-19 22:00:00 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

2025-03-31 23:00:00 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 465,80 DKK | -9,90% | 382 MDKK

2025-03-27 18:20:50 Resolutions from Zealand Pharma's Annual General Meeting 2025 553,00 DKK | +3,66% | 147 MDKK

2025-03-25 17:00:00 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. 538,50 DKK | -4,77% | 123 MDKK

2025-03-20 17:00:00 Zealand Pharma increases its share capital as a result of the exercise of employee warrants 564,00 DKK | -0,18% | 234 MDKK

2025-03-17 08:00:00 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity 578,50 DKK | -1,20% | 338 MDKK

2025-03-12 07:00:00 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity 674,00 DKK | +37,89% | 1 732 MDKK

2025-02-20 13:00:00 Zealand Pharma convenes its Annual General Meeting 2025 754,00 DKK | -2,20% | 219 MDKK

2025-02-20 10:08:58 Correction: Zealand Pharma Announces Financial Results for the Full Year 2024 754,00 DKK | -2,20% | 219 MDKK

2025-02-20 07:00:00 Zealand Pharma Announces Financial Results for the Full Year 2024 754,00 DKK | -2,20% | 219 MDKK

2025-02-13 17:00:00 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results 753,00 DKK | +0,60% | 117 MDKK

2025-01-13 17:00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 696,00 DKK | -0,43% | 152 MDKK

2025-01-07 17:00:00 Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity 720,00 DKK | +1,05% | 97,7 MDKK

2025-01-06 17:00:00 Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th 712,50 DKK | +1,06% | 86,3 MDKK

2024-12-25 17:40:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

2024-12-25 17:30:00 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

2024-12-19 20:58:00 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome 728,00 DKK | -3,77% | 1 136 MDKK

2024-12-10 15:00:00 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity 758,00 DKK | -1,56% | 105 MDKK

2024-11-13 18:00:00 Zealand Pharma to participate in the Jefferies London Healthcare Conference 801,50 DKK | -1,78% | 140 MDKK

2024-11-11 17:00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 833,50 DKK | -5,01% | 174 MDKK

2024-11-07 07:00:00 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 813,50 DKK | -5,08% | 219 MDKK

2024-11-01 17:30:00 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

2024-10-09 00:45:00 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism 803,50 DKK | +1,32% | 162 MDKK

2024-10-08 08:40:00 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide 803,50 DKK | +1,32% | 162 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Zealand Pharma

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden